03/22/2024 | Press release | Distributed by Public on 03/22/2024 00:09

Meiji Seika Pharma Presents Positive Findings from Phase III Study of Belumosudil, Selective ROCK2 Inhibitor, in Patients With Steroid-Dependent/Resistant cGVHD at JSTCT2024 in[...]

Please select the service you want to use:

• Newsvine
• Digg
• Delicious
• StumbleUpon
• Technorati
• Buzz
• Favorites
• Google Reader

 Back

 Download the original document